Natixis Advisors LLC Has $5.14 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Natixis Advisors LLC lessened its position in Glaukos Co. (NYSE:GKOS) by 9.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,299 shares of the medical instruments supplier’s stock after selling 3,439 shares during the quarter. Natixis Advisors LLC owned approximately 0.06% of Glaukos worth $5,143,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Mutual of America Capital Management LLC raised its position in Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after buying an additional 89 shares during the last quarter. HighTower Advisors LLC raised its position in Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after buying an additional 91 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after buying an additional 100 shares during the last quarter. Handelsbanken Fonder AB raised its position in Glaukos by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock valued at $2,204,000 after buying an additional 100 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Glaukos by 2.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,956 shares of the medical instruments supplier’s stock valued at $1,427,000 after buying an additional 231 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of recent research reports. Truist Financial raised their price target on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Morgan Stanley downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price target for the company. Finally, Stephens upgraded Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $102.02 on Friday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $87.31 and a 12 month high of $163.71. The stock has a 50 day moving average of $135.32 and a 200-day moving average of $136.53. The company has a market capitalization of $5.77 billion, a P/E ratio of -35.55 and a beta of 0.99.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities research analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Insider Buying and Selling

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.40% of the stock is currently owned by insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.